Intermittent Theta Burst Stimulation Attenuates Cognitive Deficits and Alzheimer's Disease-Type Pathologies via...

Area of Science:

• Neuroscience
• Mitochondrial Biology
• Neurodegenerative Diseases

Background:

• Intermittent theta burst stimulation (iTBS) is a promising non-invasive brain stimulation technique for improving cognition in Alzheimer's disease (AD).
• The precise molecular mechanisms driving iTBS-induced cognitive benefits in AD remain largely unexplored.
• Mitochondrial dysfunction is implicated in AD pathogenesis, and magnetic stimulation may influence mitochondrial activity.

Purpose of the Study:

• To elucidate the underlying mechanism of iTBS-mediated cognitive enhancement in a mouse model of AD.
• To investigate the role of mitochondrial function and iron-sulfur cluster assembly in iTBS's therapeutic effects.
• To identify a mechanistic target for iTBS in treating AD.

Main Methods:

• Utilized APP/PS1 transgenic mice, a common model for AD research.
• Administered intermittent theta burst stimulation (iTBS) to the mice.
• Assessed the expression of iron-sulfur cluster assembly 1 (ISCA1) in brain tissue.
• Performed in vivo and in vitro experiments to study mitochondrial respiration and function.
• Evaluated cognitive performance and AD-type pathologies.

Main Results:

• iTBS significantly upregulated the expression of ISCA1 in the brains of APP/PS1 mice.
• iTBS modulated mitochondrial iron-sulfur cluster assembly, enhancing mitochondrial respiration and function.
• iTBS treatment rescued cognitive decline and attenuated AD-associated pathologies in the mouse model.
• ISCA1 was identified as a key mediator of iTBS's effects on mitochondrial function.

Conclusions:

• iTBS exerts therapeutic effects in AD by enhancing mitochondrial respiration and function through ISCA1-mediated iron-sulfur cluster assembly.
• This study reveals a novel mechanism of action for iTBS in alleviating cognitive impairments and AD pathologies.
• The findings highlight ISCA1 as a potential mechanistic target for iTBS, supporting its therapeutic potential for Alzheimer's disease.